



For Internal Use Only (Case #:		Date:			\square RS \square] <i>PAP</i>		
Со	mprehensiv	ENROL P.O. Box 7588 • Phone: 888-587 Between the ho	LMENT I Overland Paragram -3263 • Fax:	FORM ark, KS 66207 866-676-4073	ertise (CO	RE)			
PATIENT INFORMA	TION: (Please t	type or print clea	arly)						
Patient Name (First M	l Last):								
Social Security #:		Date of Birth:							
Street Address:			Phone:						
City:					Zip:				
Contact Name (if othe	r than patient):			Cont	act Phone:				
Permanent U.S. Resid	lent?			Gend	ler: 🗆 Male	☐ Fem	nale		
FINANCIAL INFORM	MATION: (Pleas	e complete with	a dollar am	ount. Please d	o NOT leave	blank o	r put N/A.)		
Annual Gross Househo Attach copies of proof of persons in the household Example: Federal income	income for you and	d all dependent	_	To include you, yo	our spouse and	depende			
INSURANCE INFOR	<u> </u>								
	(,		,					
Does the patient have	** <u>PLEASE INCLUDI</u> • Medicare Covera	E COPY OF INSURAI age: ☐ YES ☐	NCE CARDS, F NO Check a	all that apply:	Part A	Part B	re Advantage		
Medicare Policy #:				Effective Date:			<u> </u>		
If has PART D or Medic									
Primary:	Insuranc	e Name:	Pr	none #:	ID / Policy	/#:	Group #:		
Secondary:									
State Program:									
Veteran or Other Plan:									
MEDICAID: ☐ Not applie	l d □ Denied □ Per	l nding VETERAN	N? YES	NO Applied fo	rVA? 🗖 YES 🕻	1 NO			
I verify that the information provid Comprehensive Oncology Reimbur guarantee acceptance into the COR Program and the related eligibility (30) days if there is any change in t Teva drug requested and/or supplied I terminate my participation in the of Patient/Legal Guardian* Signa	rsement Expertise (CORE) E Program. I also underst criteria. I authorize Teva to the status of my eligibility ed under the CORE Program in writing ture:) Program is contingent upo and that Teva reserves the rouse my Social Security nu to receive products through am. I have read, understand	on my ability to mee right at any time and amber for identifica n this Program. I ce d and agree to all of	et the eligibility criteria and d without notice to modify tion purposes and record l rtify that I have not receiv the above. Unless revoked Date:	d that completing the variety the application form exeping. I agree to not red, and will not seek d by me in writing, this	enrollment p or modify or ify the CORI to receive, re	orocess does not r discontinue this E Program within thirty eimbursement for the		
tuthorize my healthcare providers and insurance companies to disclose to Teva Pharmaceuticals ("Teva") and its agents and assignees, all medical records and information, financial and surance records and information, as well as other personal identifying information, with respect to myself, for the purpose of my enrollment or participation in the Comprehensive Oncology imbursement Expertise (CORE) Program. Although Teva will safeguard my information and only use it for the intended purposes, I understand this information may be subject to resclosure and no longer protected by federal privacy rules. My right to treatment, payment for treatment, or insurance enrollment, eligibility for insurance benefits is not conditioned on me maining this authorization. I may revoke this authorization at any time, except to the extent action may have already been taken based on this authorization, by sending notice in writing to P.O. ax 7588, Overland Park, KS 66207, Attn: Chief Privacy Officer. Unless revoked, this authorization will remain in effect until I terminate my participation in the CORE Program. **Please provide a description of the Legal Guardian's authority to act for the patient*									
	*	Please provide a description of	the Legal Guardian's	authority to act for the patient		-			

Please Fax Completed Form to 866-676-4073



Physician Signature:_

Case #: Date: \square RS \square PAP For Internal Use Only

Comprehensive Oncology Reimbursement Expertise (CORF)

ENROLLMENT FORM P.O. Box 7588 • Overland Park, KS 66207 Phone: 888-587-3263 • Fax: 866-676-4073 Between the hours of 9 AM and 8 PM (ET)									
PHYSICIAN IN	FORMATION	: (Please type or prin	t clearly)						
Physician Name:					DEA #:				
		Medical License #: MD Tax ID #:							
Facility Name:				_ Group	oTax ID #:				
City:					State: Zip:				
Medicaid Provider				PTAN#:	<u> </u>				
Clinical Contact:				Contact					
Contact Phone:		Ext:			act Fax:				
Billing Contact:					t Title:				
Contact Phone:		Ext:			act Fax:				
PRESCRIBING	INFORMATI	ON:							
Patient Name (Fir	st MI Last):			ate of Bir					
Site of Care:		Is patient being treated outpatient? □Yes □No							
Patient Primary D			Description:						
Patient Secondar		D-10 Code:	Description	n:					
Clinical History/Fa Choose Drug Name □ BENDEKA TM (be □ SYNRIBO® (oma	e: endamustine hvdro	chloride) Injection ロTREAI	NDA [®] (bendam utaneous use	ustine hyd	lrochloride) lı X [®] (tbo-filgra	njection □ TRISENOX [®] (arsenic trioxide) injection astim) Injection			
Therapy GIVEN:				Therapy PLANNED for month:					
Date(s):	Dose:	Frequency:	Date(s):		Dose:	Frequency:			
DISTRIBUTION	N:								
	s is the same as	the mailing address abo ipping Address Is Sam				the box. If not, please indicate shipping			
City:				State:	-	Zip:			
ne best of my knowledge and inder the program. I certify the program. I certify that no free eimbursement of product alreendered in conjunction with the parties of the patient may no loolicy change allows for reimbine product when necessary, prescribing a Teva drug. I und will be required to appeal the cost required: (i) I will submit a cost required: (i) I will submit a cost required: (ii) I will submit a cost required: (ii) I will submit a cost required: (ii) I will submit a cost required: (iii) I will submit a cost required in the cost required	that I have prescribed the at I have not received, a eproduct provided under eady supplied at no charme administration of a protent any participation in the onger be eligible under the ursement of product alreading and that I am uterstand that I am uterstand that Teva and its denial from patient's insurtation to the patient's insurta	e drug specified in this application based will not seek to receive, reimbursem rethis Program will be distributed for sage, Teva will bill me for the covered product provided under this program, I agree Program and to notify a Program represse Frogram. I agree to immediately notify supplied at no charge. I understand under no obligation to prescribe any Teagents are not responsible for filing any ance company before receiving any program.	d on my professional ent for any drug requale to any individual roduct, and I agree to fully disclose to sentative if aspects of a Program representative trava reserves to va drug to participate or insurance claim. Product under this programined I will submit an	judgment of ruested, replace or organization of the insurance of my certification and the insurance of the i	medical necessity. Led and/or supplie Led on or returned for Led to payment of Led company that the Led tion are no longer Led to terminate the Led	Ittest that the information contained in this form is complete and accurate a Lunderstand that the patient must meet financial parameters to be eligical under the Comprehensive Oncology Reimbursement Expertise (COF credit. I understand that if a retroactive insurer policy change allows of the bill. If I submit a claim to patient's insurance company for service product was provided free of charge under this Program. I agree to about a rapplicable. I understand that if the patient's income or insurance state patient's insurance or income status changes, or if a retroactive insurance program at any time without prior notice and reserves the right to revive not received, nor will I receive any benefit from Teva or its agents, were of circumstances, as described in CORE Program supporting material with these requirements and certify that in circumstances where an appleace company, prior to requesting free product under this Program. If product company, prior to requesting free product under this Program.			

Please Fax Completed Form to 866-676-4073

Date:

 $@ 2016 \ Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries \ Ltd. \\ ONC-40894 \ March 2016 \ Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries \ Ltd. \\ ONC-40894 \ March 2016 \ March 2$